Switch theme
Sign up to access all valuation multiples
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
2000
164
LTM Revenue $264M
LTM EBITDA $66.4M
$778M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Basilea Pharmaceutica has a last 12-month revenue (LTM) of $264M and a last 12-month EBITDA of $66.4M.
In the most recent fiscal year, Basilea Pharmaceutica achieved revenue of $258M and an EBITDA of $82.1M.
Basilea Pharmaceutica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Basilea Pharmaceutica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $264M | XXX | $258M | XXX | XXX | XXX |
| Gross Profit | $216M | XXX | $210M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $66.4M | XXX | $82.1M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $72.8M | XXX | $75.7M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $75.7M | XXX | $96.1M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 37% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Basilea Pharmaceutica's stock price is CHF 52 (or $64).
Basilea Pharmaceutica has current market cap of CHF 638M (or $790M), and EV of CHF 629M (or $778M).
See Basilea Pharmaceutica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $778M | $790M | XXX | XXX | XXX | XXX | $5.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Basilea Pharmaceutica has market cap of $790M and EV of $778M.
Basilea Pharmaceutica's trades at 3.0x EV/Revenue multiple, and 9.5x EV/EBITDA.
Equity research analysts estimate Basilea Pharmaceutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Basilea Pharmaceutica has a P/E ratio of 10.4x.
See valuation multiples for Basilea Pharmaceutica and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $790M | XXX | $790M | XXX | XXX | XXX |
| EV (current) | $778M | XXX | $778M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.7x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBIT | 10.7x | XXX | 10.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.4x | XXX | 8.2x | XXX | XXX | XXX |
| EV/FCF | 25.9x | XXX | 8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBasilea Pharmaceutica's last 12 month revenue growth is 12%
Basilea Pharmaceutica's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.8M for the same period.
Basilea Pharmaceutica's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Basilea Pharmaceutica's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Basilea Pharmaceutica and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 58% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Basilea Pharmaceutica acquired XXX companies to date.
Last acquisition by Basilea Pharmaceutica was XXXXXXXX, XXXXX XXXXX XXXXXX . Basilea Pharmaceutica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Basilea Pharmaceutica founded? | Basilea Pharmaceutica was founded in 2000. |
| Where is Basilea Pharmaceutica headquartered? | Basilea Pharmaceutica is headquartered in Switzerland. |
| How many employees does Basilea Pharmaceutica have? | As of today, Basilea Pharmaceutica has 164 employees. |
| Is Basilea Pharmaceutica publicy listed? | Yes, Basilea Pharmaceutica is a public company listed on SWX. |
| What is the stock symbol of Basilea Pharmaceutica? | Basilea Pharmaceutica trades under BSLN ticker. |
| When did Basilea Pharmaceutica go public? | Basilea Pharmaceutica went public in 2004. |
| Who are competitors of Basilea Pharmaceutica? | Similar companies to Basilea Pharmaceutica include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Basilea Pharmaceutica? | Basilea Pharmaceutica's current market cap is $790M |
| What is the current revenue of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12 months revenue is $264M. |
| What is the current revenue growth of Basilea Pharmaceutica? | Basilea Pharmaceutica revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Basilea Pharmaceutica? | Current revenue multiple of Basilea Pharmaceutica is 3.0x. |
| Is Basilea Pharmaceutica profitable? | Yes, Basilea Pharmaceutica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12 months EBITDA is $66.4M. |
| What is Basilea Pharmaceutica's EBITDA margin? | Basilea Pharmaceutica's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Basilea Pharmaceutica? | Current EBITDA multiple of Basilea Pharmaceutica is 11.7x. |
| What is the current FCF of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12 months FCF is $30.0M. |
| What is Basilea Pharmaceutica's FCF margin? | Basilea Pharmaceutica's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Basilea Pharmaceutica? | Current FCF multiple of Basilea Pharmaceutica is 25.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
